Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 4Endometrial Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Peripheral Nervous System Diseases 1Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 6Nivolumab 3Cisplatin 3Carboplatin 3Paclitaxel 2Fluorouracil 2tucatinib 1pertuzumab 1milademetan 1lenvatinib 1cemiplimab 1Trastuzumab 1Tomography, X-Ray Computed 1Ritonavir 1Radiation 1Prednisone 1Prednisolone 1Positron-Emission Tomography 1Pemetrexed 1Oxaliplatin 1Magnetic Resonance Imaging 1Leucovorin 1Itraconazole 1Gemcitabine 1Fulvestrant 1Cetuximab 1Capecitabine 1Brachytherapy 1Bevacizumab 1AZD9833 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × Prednisolone × Gynecologic × Clear all
NCT05489211 2026-03-19

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

AstraZeneca

Phase 2 Recruiting
454 enrolled
GastrointestinalGynecologic

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡